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ABSTRACT
We evaluated the prevalence and prognostic value of
CT-pulmonary angiographic (CTPA) measures in 292
treatment naive patients with pulmonary arterial
hypertension (PAH). Pulmonary artery calciﬁcation (13%)
and thrombus (10%) were exclusively seen in PAH-
congenital heart disease. Oesophageal dilation (46%)
was most frequent in PAH-systemic sclerosis. Ground
glass opaciﬁcation (GGO) (41%), pericardial effusion
(38%), lymphadenopathy (19%) and pleural effusion
(11%) were common. On multivariate analysis, inferior
vena caval area, the presence of pleural effusion and
septal lines predicted outcome. In PAH, CTPA provides
diagnostic and prognostic information. In addition, the
presence of GGO on a CT performed for unexplained
breathlessness should alert the physician to the
possibility of PAH.
INTRODUCTION
Pulmonary hypertension (PH) ranges from a mild
elevation in pressure in severe cardiac/respiratory
disease to rare conditions where severe pressure
elevation results in right heart failure and death.
The current classiﬁcation identiﬁes 5 major groups,
deﬁning prognosis and treatment. Classiﬁcation
within groups is also important. In pulmonary
arterial hypertension (PAH), survival in idiopathic
PAH (IPAH) is superior to PAH associated with
connective tissue disease (PAH-CTD) but inferior
to PAH associated with congenital heart disease
(PAH-CHD).1
Due to the heterogeneity of PH, imaging is recog-
nised as a valuable tool improving phenotyping and
providing prognostic information, complementing
data from right heart catheterisation. Cardiac MR
provides functional information whereas CT pro-
vides structural information, depicting features
which may cause and be due to PH. Previous CT
studies in PH have mainly been in mixed groups;
only a small number of CT parameters have been
studied and prognostic data are limited. Our object-
ive was to systematically evaluate the prevalence,
diagnostic and prognostic value of vascular, cardiac,
parenchymal and mediastinal CT ﬁndings in
patients with PAH at the time of diagnosis.
METHODS
Consecutive treatment naive patients with PAH
were identiﬁed from the ASPIRE Registry1 of
patients referred to a PH referral centre.
Classiﬁcation was by standard criteria following
multidisciplinary assessment. Inclusion criteria
required the patient to have undergone multislice
CT-pulmonary angiography (CTPA) and high reso-
lution computed tomography (HRCT) within
3 months of initial diagnostic right heart catheter-
isation (RHC), except for Eisenmenger’s syndrome
in whom RHC was not routinely performed.
Image analysis and interpretation: see online
supplement.
Vascular changes: Pulmonary artery to aorta ratio
(PA to Ao ratio), depth of pericardial effusion,
reﬂux of contrast into the hepatic veins and inferior
vena cava (IVC) cross-sectional area were measured
(ﬁgures 1 and 2).
Cardiac changes: Right ventricle to left ventricle
ratio (RV to LV ratio), right atrial size, interventri-
cular (IV) septal position and RV free wall thickness
were recorded (ﬁgure 3).
Parenchymal and mediastinal changes: The pres-
ence of ground glass opaciﬁcation (GGO) and the
pattern/distribution was noted (ﬁgure 4). CT scans
were assessed for ﬁbrosis, pleural effusions, medias-
tinal lymphadenopathy and dilated bronchial
collaterals.
RESULTS
Of 444 consecutive patients with PAH from the
ASPIRE Registry (2006–2010), 292 patients had mul-
tislice CTPA/HRCT within 3 months of right heart
catheterisation; mean age, 62±16 years (table 1) (see
online supplement for haemodynamic and demo-
graphic characteristics, ﬁgure 5 and online supplemen-
tary table S2).
Vascular changes
The PA to Ao ratio was highest for patients with
PAH-CHD-Eisenmenger followed by IPAH.
Greater IVC dilatation was observed in PAH-portal
and PAH-CHD. Regurgitation of contrast into
hepatic veins was frequent across the subgroups. PA
calciﬁcation and mural thrombus were noted only
in patients with PAH-CHD and occurred in 16%
(calciﬁcation) and 13% (mural thrombus) in
PAH-CHD-Eisenmenger group.
Cardiac changes
The RV to LV ratio for PAH was 1.25±0.42 (mean
±SD) highest in IPAH although there were no
statistically signiﬁcant differences between groups.
The RV wall thickness was 6±2.7 mm for PAH and
Open Access
Scan to access more
free content
382 Rajaram S, et al. Thorax 2015;70:382–387. doi:10.1136/thoraxjnl-2014-206088
Chest clinic
Ch
es
t
cl
in
ic
within subgroups less RV hypertrophy was seen in PAH-CTD
(PAH systemic sclerosis (PAH-SSc) and PAH-CTD-non-SSc).
Mean right atrium (RA) size for PAH was 55 mm±12.1.
Qualitative grading of the RA showed 82% had right atrial
enlargement. A higher proportion of patients with IPAH and
PAH-CHD were graded as severe RA enlargement compared
with other subgroups. Deviation of the IV septum towards the
LV was evident in 27% of patients with PAH and most frequent
in IPAH. A pericardial effusion was seen in 38% of patients
most frequently in patients with PAH-CTD-non-SSc and least
frequently in PAH-CHD-Eisenmenger.
Parenchymal and mediastinal changes
Ground glass opacities were frequent in PAH (41%), most com-
monly PAH-CHD. The predominant pattern of GGO in PAH
was a centrilobular pattern. In PAH-SSc, 51% of patients had
central distribution of GGO and 49% had non-central distribu-
tion; compared with a low occurrence of central distribution in
other subgroups.
Dilated collateral vessels occurred most commonly in patients
with PAH-CHD-Eisenmenger syndrome.
Survival results
The maximal duration of follow-up was 6 years (mean 3 years)
and there were 112 deaths. Multivariable Cox proportional
hazard analysis incorporating clinical, haemodynamic and CT
parameters showed CT parameters, inferior vena caval area and
Figure 1 The pulmonary artery (PA) aorta ratio was obtained by
measuring the widest transverse diameter of the PA (blue) and the
corresponding transverse diameter of aorta (red).
Figure 2 Grading of tricuspid regurgitation. (A) 0=There is no reﬂux into IVC, (B) 2=reﬂux into IVC but not hepatic veins, (C) 3=reﬂux into IVC
and proximal hepatic veins and (D) 4=reﬂux into IVC and distal hepatic veins.
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the presence of pleural effusion/septal lines to be signiﬁcant pre-
dictors of death (see online supplementary tables S3 and S4 and
ﬁgures 2 and 6).
DISCUSSION
This study is the ﬁrst comprehensive report of the prevalence
and relative prognostic value of vascular, cardiac, lung parenchy-
mal and mediastinal changes on CT in PAH and its major sub-
groups. Within subgroups, different vascular and cardiac
conﬁgurations are observed, reﬂecting the heterogeneity of
PAH. We have demonstrated that cardiac and vascular morpho-
logy can predict outcome in PAH and CT measures such as IVC
area, and pleural effusion/septal lines are independent prognos-
tic markers.
In addition to established measures, quantiﬁable CT ﬁndings
including elevated RV to LV ratio, deviated IV septum, dilated
RA, RV free wall hypertrophy, pericardial/pleural effusions, con-
trast regurgitation into the hepatic veins and GGO occur fre-
quently in PAH and major subgroups.
Different CT patterns were observed in PAH subgroups but
none were diagnostic. IPAH and PAH-CHD-Eisenmenger have a
higher proportion of severe RA dilatation, contrast regurgitation
into hepatic veins and ground glass opacities. While more
patients with IPAH have a deviated IV septum and greater RV
to LV ratio, the Eisenmenger group had a higher PA to Ao ratio,
PA calciﬁcation, mural thrombus and dilated collateral vessels.
Although the higher RV to LV ratio in IPAH may appear
counterintuitive, this may reﬂect better preserved RV function
in the conditioned RV of the Eisenmenger patient and the off-
loading effect of a right-left shunt. We noted that central distri-
bution of ground glass opacity was frequent in patients with
PAH-SSc whereas a centrilobular pattern was more common in
IPAH and PAH-CHD-Eisenmenger.
CT features predict outcome in treatment naive PAH including
RV to LV ratio, right atrial size, IV septal position, inferior vena
caval size, pericardial/pleural effusions, mediastinal lymphadenop-
athy and septal lines. Most of these parameters predict survival in
major subgroups (see online supplementary table S4). IVC area the
presence of pleural effusions/septal lines were predictors of
outcome independent of pulmonary haemodynamics and WHO
functional class, highlighting the prognostic value of CT.2 In PAH,
RV function is a prognostic determinant. IV septal displacement
and dilatation of RV as shown by a high RV to LV ratio on CT
reﬂect a failing RV and it is not surprising they have prognostic
signiﬁcance. A failing RV and tricuspid regurgitation elevate right
atrial pressure. Inferior vena caval size was demonstrated to be
a strong predictor of outcome. Vena caval diameter reﬂects the
pressure in the RA2 which is an important prognostic marker in
PAH. Elevated right atrial pressure impedes mediastinal lymphatic
and venous drainage resulting in the development of septal lines,
mediastinal lymphadenopathy and pleural and pericardial
Figure 3 (A) The maximum mid-transverse diameters of the RV (right arrow) and LV (left arrow) cavities were measured in the axial plane at their
widest points between the inner surfaces of the free wall and the interventricular septum. (B) For assessing the right atrial margin (arrow) on CT,
right atrial length was measured from the centre of tricuspid annulus to the superior right atrial margin. RV, right ventricle; LV, left ventricle.
Figure 4 Centrilobular ground glass pattern (A) and central ground glass pattern (B).
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Table 1 Features seen on CT-pulmonary angiography in patients with pulmonary arterial hypertension (PAH) and its major subgroups
CT parameters
PAH
(n=292)
IPAH
(n=74) PAH-SSc (n=95)
PAH-CTD-non-SSc
(n=39)
PAH-portal
(n=14)
PAH-CHD
(n=63)
PAH-CHD-
Eisenmenger
(n=31)Vascular changes
PA to Ao ratio∼ 1.16 (0.21) 1.19 (0.18)* 1.04 (0.16)* 1.07 (1.16)* 1.08 (0.17)* 1.26 (0.40)†‡§*¶ 1.46 (0.45)
IVC size (mm2)∼ 596 (207) 583 (200) 570 (203) 546 (206) 632 (156) 647 (209) 659 (212)
TR present 73 80 67 62 57 85 93
Grade 1 18 15 20 23 36 14 16
Grade 2 21 24 23 15 14 19 23
Grade 3 12 16 13 13 0 8 22
Grade 4 22 24 12 10 7 44 32
Calcification in PA 3 0 0 0 0 13 16
Thrombus in PA 2 0 0 0 0 10 13
Cardiac changes
RV to LV ratio 1.25 (0.42) 1.39 (0.46) 1.19 (0.48) 1.19 (0.36) 1.25 (0.35) 1.15 (0.30) 1.23 (0.38)
RVH (mm) 6 (2.7) 6 (2.3)‡ 4 (1.78)*¶ 4 (3.21)* 6 (1.89) 7 (4.26)§‡ 8 (2.5)
RA size (mm) 55 (12.1) 57 (10.9) 53 (12.5)* 52 (13.1)* 56 (17.2) 59 (13.4)§‡ 59 (14.6)
RA size
Moderate 28 35 20 26 36 35 42
Severe 20 24 16 10 14 27 22
IV septum
Flattened 31 42 24 26 43 30 29
Deviated 27 34 19 21 21 33 29
Pericardial effusion
Present 38 38 36 53 42 48 30
Depth (mm)∼ 12 (5) 8 (7) 14 (6) 13 (6) 14 (5) 13 (4) 11 (4)
Lung and mediastinal changes
GGO present 41 42 36 24 21 60 58
Central pattern** 21 10 51 10 2 5 6
Centrilobular pattern** 55 48 61 60 67 53 56
Collaterals vessel 11 9 1 8 0 35 55
Lymphadenopathy 19 22 25 27 0 10 16
Pleural effusion 11 14 15 8 14 5 3
Septal lines 21 30 23 5 21 18 23
Ascites 5 5 4 8 14 2 0
Oesophageal dilatation 23 7 46 36 7 6 10
Frequency is expressed as a percentage; for absolute values, data are expressed as mean (SD).
*p<0.05 in comparison with PAH-CHD.
†p<0.05 in comparison with PAH-portal.
‡p<0.05 in comparison with PAH-SSc.
§p<0.05 in comparison with PAH-CTD-non-SSc.
¶p<0.05 in comparison with IPAH.
**Represents percentage of the patients with GGO present.
Ao, aorta; CHD, congential heart disease; CTD, connective tissue disease; GGO, ground glass opacification; IPAH, idiopathic pulmonary arterial hypertension; IV, interventricular; IVC, inferior vena cava; LV, left ventricle; PA, pulmonary artery; PAH,
pulmonary arterial hypertension; RA, right atrium; RV, right ventricle; RVH, right ventricular hypertrophy; TR, tricuspid regurgitation; SSc-systemic sclerosis.
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effusions. These features are not surprisingly associated with a
poor outcome.
Ground glass attenuation is described in patients with PH.3
Our results show that GGO is seen in all major subgroups of
PAH. Centrilobular pattern of GGO correlated with poor
outcome following treatment in patients with PAH in a previous
study.4 In our study, this prognostic observation was restricted
to IPAH and was not seen in other major subgroups. We found
a lower prevalence of GGO/septal lines in PAH-SSc than may
have been expected but this reﬂects the rigorous way that
patients with SSc with coexisting lung disease are excluded in
the ASPIRE Registry, with this group having an FVC of 95
±14% (see online supplement).
So how does an appreciation of CT characteristics in PAH
help the physician? First, although there is overlap in the differ-
ent forms of PAH, the presence of a ground glass pattern affect-
ing the central part of the lung and sparring the periphery with
oesophageal dilation should raise the possibility of underlying
systemic sclerosis, whereas a centrilobular ground glass pattern
with a very large PA and luminal calciﬁcation should suggest the
possibility of an underlying congenital heart problem and
prompt further investigation to conﬁrm or refute these diagno-
ses. Second, the presence of adverse prognostic features on CT
such as the presence of a pleural effusion, septal lines or a
dilated IVC should alert the physician that the patient falls into
a poor prognostic group prompting urgent referral for specialist
assessment and treatment. Given that CT results in radiation
exposure and there are other validated biomarkers which are
sensitive to change, its use in follow-up is not recommended.
Whether a reduction in IVC area or resolution of pleural effu-
sions/septal lines is of prognostic importance is not answered by
this study. Finally, a centrilobular ground glass pattern is very
common in PAH and its presence should alert the physician to
the possibility of PAH if the scan was performed for unex-
plained breathlessness and be a prompt to look for other CT
features such as PA and RVenlargement, which are seen in PH.
There are limitations to our study. We used non-gated axial
images. However, the purpose of our study was to evaluate
uncomplicated measurements in a non-gated CT frequently per-
formed as a ﬁrst line examination. Second, pulmonary
veno-occlusive disease (PVOD) has several overlapping clinical
and pathological features with IPAH, which are difﬁcult to rec-
ognise without lung biopsy or transplantation. It is possible that
patients with PAH in our cohort may have had PVOD, although
the number of patients found to have histological evidence of
PVOD in a previous study at postmortem was low.5 In this
Figure 5 Flow chart demonstrating patient inclusion.
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cohort of patients, the majority of patients were in WHO func-
tional capacity III and IV, comparable with the majority of
Registry data from this era. Some more recent reports have iden-
tiﬁed a higher proportion of patients with earlier stage disease.
In conclusion, we report features of PAH and its major sub-
groups on a pretreatment CTand demonstrate that CT measures
including the presence of pleural effusion/septal lines and infer-
ior vena caval area predict outcome. Finally, GGO is commonly
seen in PAH and its presence on a CT performed for breathless-
ness should raise the possibility of this diagnosis.
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